These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 32949266

  • 1. Population pharmacokinetics and renal toxicity of cisplatin in cancer patients with renal dysfunction.
    Morita-Ogawa T, Sugita H, Minami H, Yamaguchi T, Hanada K.
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):559-566. PubMed ID: 32949266
    [Abstract] [Full Text] [Related]

  • 2. Validity of new methods to evaluate renal function in cancer patients treated with cisplatin.
    Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Tomioka H, Umezu M, Otsuki N, Nibu K, Minami H.
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):281-8. PubMed ID: 26791871
    [Abstract] [Full Text] [Related]

  • 3. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
    Chen R, Li J, Hu WW, Wang ML, Zou SL, Miao LY.
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
    [Abstract] [Full Text] [Related]

  • 4. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients.
    Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, Ohno T, Masuhara K, Tanaka Y, Kato K, Nagai H, Yokoyama A, Kurita Y.
    Cancer Chemother Pharmacol; 1996 Nov; 39(1-2):131-7. PubMed ID: 8995510
    [Abstract] [Full Text] [Related]

  • 5. Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.
    Ogawa T, Niho S, Nagai S, Kojima T, Nishimura Y, Ohe Y, Kondo N, Yamaguchi T, Endo K, Izumi K, Minami H.
    Int J Clin Oncol; 2013 Dec; 18(6):977-82. PubMed ID: 23053402
    [Abstract] [Full Text] [Related]

  • 6. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program.
    Nagai N, Ogata H, Wada Y, Tsujino D, Someya K, Ohno T, Masuhara K, Tanaka Y, Takahashi H, Nagai H, Kato K, Koshiba Y, Igarashi T, Yokoyama A, Kinameri K, Kato T, Kurita Y.
    J Clin Pharmacol; 1998 Nov; 38(11):1025-34. PubMed ID: 9824784
    [Abstract] [Full Text] [Related]

  • 7. Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy.
    Klöckl MC, Kasparek AK, Riedl JM, Moik F, Mollnar S, Stotz M, Szkandera J, Terbuch A, Gerger A, Niedrist T, Pichler M, Bauernhofer T, Schilcher G, Zitta S, Rosenkranz AR, Friedl C, Stöger H, Posch F.
    Sci Rep; 2020 Jul 08; 10(1):11219. PubMed ID: 32641710
    [Abstract] [Full Text] [Related]

  • 8. Impact of acute kidney injury defined by CTCAE v4.0 during first course of cisplatin-based chemotherapy on treatment outcomes in advanced urothelial cancer patients.
    Ishitsuka R, Miyazaki J, Ichioka D, Inoue T, Kageyama S, Sugimoto M, Mitsuzuka K, Matsui Y, Shiraishi Y, Kinoshita H, Wakeda H, Nomoto T, Kikuchi E, Kawai K, Nishiyama H.
    Clin Exp Nephrol; 2017 Aug 08; 21(4):732-740. PubMed ID: 27565169
    [Abstract] [Full Text] [Related]

  • 9. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
    Yoshida T, Niho S, Toda M, Goto K, Yoh K, Umemura S, Matsumoto S, Ohmatsu H, Ohe Y.
    Jpn J Clin Oncol; 2014 Apr 08; 44(4):346-54. PubMed ID: 24503028
    [Abstract] [Full Text] [Related]

  • 10. Population pharmacokinetics of cisplatin in adult cancer patients.
    de Jongh FE, Gallo JM, Shen M, Verweij J, Sparreboom A.
    Cancer Chemother Pharmacol; 2004 Aug 08; 54(2):105-12. PubMed ID: 15127229
    [Abstract] [Full Text] [Related]

  • 11. [Effects of Renal Function Evaluation with or without Serum Creatinine Adjustment on Cisplatin/Fluorouracil Therapy for Cervical Cancer].
    Takagi M, Sagara A, Ishizawa A, Ito A, Miyazaki M, Senzaki K, Nagai T, Yamada K.
    Yakugaku Zasshi; 2019 Aug 08; 139(10):1327-1332. PubMed ID: 31582618
    [Abstract] [Full Text] [Related]

  • 12. [Incidence, risk factors and prevention of cisplatin-induced nephrotoxicity in patients with lung cancer].
    Losonczy G, Máthé C, Müller V, Szondy K, Moldvay J.
    Magy Onkol; 2010 Dec 08; 54(4):289-96. PubMed ID: 21163759
    [Abstract] [Full Text] [Related]

  • 13. Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.
    Fukushima K, Okada A, Sasaki K, Kishimoto S, Fukushima S, Hamori M, Nishimura A, Shibata N, Shirai T, Terauchi R, Kubo T, Sugioka N.
    J Pharm Sci; 2016 Jan 08; 105(1):324-32. PubMed ID: 26852862
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients.
    Erdlenbruch B, Nier M, Kern W, Hiddemann W, Pekrun A, Lakomek M.
    Eur J Clin Pharmacol; 2001 Aug 08; 57(5):393-402. PubMed ID: 11599657
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of methods of assessment of renal function in patients with cancer treated with cisplatin, carboplatin or methotrexate.
    Robinson BA, Frampton CM, Colls BM, Atkinson CH, Fitzharris BM.
    Aust N Z J Med; 1990 Oct 08; 20(5):657-62. PubMed ID: 2285382
    [Abstract] [Full Text] [Related]

  • 20. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002.
    Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K.
    Jpn J Clin Oncol; 2013 Nov 08; 43(11):1115-23. PubMed ID: 24082005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.